The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Subscribe To Our Newsletter & Stay Updated
